Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity Published June 22, 2025 N Engl J Med 2025;393:635-647 DOI: 10.1056/NEJMoa2502081 Abstract Background Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials
Research on these peptides is also contributing to a deeper understanding of angiogenesis, cell migration, vascular signaling, and regenerative processes, which may ultimately support the development of future therapeutic strategies
But theyre not a one-size-fits-all fix, and theyre not appropriate for everyone
This was a day after the Australian Crime Commission released a report confirming the widespread use of illegal drugs, including peptides, in Australian sport and links to criminals, prompting the former head of ASADA, Richard Ings, to call it the ''blackest day'' in sport
Not everyone needs every peptide, and staggered implementation helps identify the minimum effective stack